Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply

Published:2021-10-01 Issue:10 Volume:7 Page:1579
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Del Paggio Joseph C.¹,Eisenhauer Elizabeth A.²,Booth Christopher M.²³

Affiliation:

1. Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada

2. Department of Oncology, Queen’s University, Kingston, Ontario, Canada

3. Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2783529/jamaoncology_del_paggio_2021_lr_210024_1634002314.46924.pdf

Reference6 articles.

1. Evolution of the randomized clinical trial in the era of precision oncology.;Del Paggio;JAMA Oncol,2021

2. Informing patients about expected outcomes: the efficacy-effectiveness gap.;Templeton;J Clin Oncol,2020

3. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?;Kemp;BMC Med,2017

4. Association between progression-free survival and patients’ quality of life in cancer clinical trials.;Hwang;Int J Cancer,2019

5. Progression-free survival: meaningful or simply measurable?;Booth;J Clin Oncol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs;Journal of Clinical Oncology;2023-11-10

2. Oncologic end points and implication of trial design in the era of immunotherapy for resectable non–small cell lung cancer;The Journal of Thoracic and Cardiovascular Surgery;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3